Skip to content
HeyJared

The Uromigos

Broadcasting the latest developments in GU cancerHosted by Brian Rini and Tom Powles Brian Rini MD is an Ingram Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer CenterTom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and…

Podcast · By The Uromigos · English · Official site

Indexed episodes, last 90 days
7
Latest publication
Sep 28, 2026
Audience
Checking…
Earliest in this view
Jul 6, 2026

Latest episodes

  1. Episode · Sep 28, 2026

    Episode 518: PSMAddition in Clinical Practice (opens the original)

    Episode notes

    Read excerpt

    Rob Dreicer joins the show to discuss the FDA approval of Lutetium Lu 177 in the mHSPC space and how to contextualize the benefit/risk

  2. Episode · Aug 31, 2026

    Episode 517: Casdatifan Clinical Data in RCC and Translational Correlates (opens the original)

    Episode notes

    Read excerpt

    Toni Choueiri joins Brian and Tom to discuss a recent Nature paper regarding the novel HIF inhibitor, casdatifan, and biomarkers of response.

  3. Episode · Aug 17, 2026

    Episode 516: The Influence of Hypoxia on Response and Resistance in RCC (opens the original)

    Episode notes

    Read excerpt

    Ari Hakimi and Lyn Voung from MSKCC join Brian and Tom to discuss their recent Cancer Cell paper exploring the mechanistic impact of TKI-induced hypoxia on immune response in RCC.

  4. Episode · Aug 3, 2026

    Episode 515: PROTEUS - A Reflection on the Data and Controversies with Neha Vapiwala (opens the original)

    Episode notes

    Read excerpt

    Brian and Tom invite Neha Vapiwala, a Radiation Oncologist, to discuss areas of consensus and controversy from the PROTEUS trial of ADT +/- apalutamide in high-risk localized prostate cancer.

  5. Episode · Jul 20, 2026

    Episode 514: Artificial Intelligence in Cancer Drug Development (opens the original)

    Episode notes

    Read excerpt

    Travis Zack, CMO of Open Evidence, joins Brian and Tom to discuss the emergence of AI across the spectrum on cancer, drug development and application of data.

Publishing over time

Last 90 days. Choose a month to open its work.

Recurring subjects

Named in the text we hold. One piece can cover several.

Not enough subject data for this period yet.

Audience

No verified audience measurement yet.

About this data

Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.

Identity or attribution wrong? Suggest a correction.

See coverage about The Uromigos